Given this evidence, it is tempting to propose that anti-CD33 mAb could be employed in HIV-1 infection, with a potential dual beneficial effects of reducing HIV-1 replication and improving HIV-1-associated neurocognitive deficits. The gene discussed is CD33; the disease is HIV-1 infection.